These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7554803)

  • 1. Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD127371) and fleroxacin (Ro 23-6240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates.
    Jones RN; Johnson DM
    Diagn Microbiol Infect Dis; 1995 Apr; 21(4):209-13. PubMed ID: 7554803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.
    Cormican MG; Jones RN
    J Antimicrob Chemother; 1995 Aug; 36(2):431-4. PubMed ID: 8522474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
    Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interpretive criteria for susceptibility testing of CI-960 (PD127391, AM-1091), fleroxacin, lomefloxacin, and temafloxacin against Neisseria gonorrhoeae, including drug stability in GC agar medium.
    Erwin ME; Jones RN
    J Clin Microbiol; 1992 May; 30(5):1170-3. PubMed ID: 1316366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interpretive criteria for CI-960, fleroxacin and temafloxacin susceptibility tests with Haemophilus influenzae.
    Barrett MS; Jones RN
    Eur J Clin Microbiol Infect Dis; 1992 May; 11(5):462-5. PubMed ID: 1330563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interpretive criteria for CI-960 (AM-1091, PD127391) disk diffusion tests using 5-microgram disks.
    Jones RN; Erwin ME; Barrett MS
    Diagn Microbiol Infect Dis; 1992; 15(4):379-81. PubMed ID: 1319303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).
    Cormican MG; Marshall SA; Jones RN
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):51-4. PubMed ID: 7789097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reevaluations of disk diffusion susceptibility testing interpretive criteria for lomefloxacin and norfloxacin using fluoroquinolone-resistant isolates.
    Cormican MG; Jones RN
    Diagn Microbiol Infect Dis; 1995 Apr; 21(4):227-30. PubMed ID: 7554807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter study on the comparative in vitro activity of fleroxacin and three other quinolones: an interim report from 27 centers.
    Beskid G; Prosser BL
    Am J Med; 1993 Mar; 94(3A):2S-8S. PubMed ID: 8383919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of quinolone-resistant Neisseria gonorrhoeae.
    Kam KM; Wong PW; Cheung MM; Ho NK
    J Clin Microbiol; 1996 Jun; 34(6):1462-4. PubMed ID: 8735098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpretive criteria for DU-6859a disk diffusion tests using 5-micrograms disks.
    Jones RN; Johnson DM; Erwin ME
    Diagn Microbiol Infect Dis; 1994 Feb; 18(2):125-7. PubMed ID: 8062531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS; Mazens-Sullivan MF; Bartlett RC
    Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates.
    Sutton LD; Jones RN
    J Clin Microbiol; 1995 Jan; 33(1):146-8. PubMed ID: 7699031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin.
    Harrington GD; Zarins LT; Ramsey MA; Bradley SF; Kauffman CA
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):27-31. PubMed ID: 7789094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial activity of trovafloxacin tested against ciprofloxacin-susceptible and -resistant Neisseria gonorrhoeae. Interpretive criteria and comparisons with Etest results.
    Jones RN; Barrett MS; Deguchi T
    Diagn Microbiol Infect Dis; 1997 Aug; 28(4):193-200. PubMed ID: 9327248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activities of T-3262, NY-198, fleroxacin (AM-833; RO 23-6240), and other new quinolone agents against clinically isolated Chlamydia trachomatis strains.
    Maeda H; Fujii A; Nakata K; Arakawa S; Kamidono S
    Antimicrob Agents Chemother; 1988 Jul; 32(7):1080-1. PubMed ID: 2847640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-resistance and cross-susceptibility between fluoroquinolone agents.
    Barry AL; Fuchs PC
    Eur J Clin Microbiol Infect Dis; 1991 Dec; 10(12):1013-8. PubMed ID: 1666360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RO 23-6240 (AM-833), a new fluoroquinolone: in vitro antimicrobial activity and tentative disk diffusion interpretive criteria.
    Fuchs PC; Jones RN; Barry AL; Ayers LW; Gavan TL; Gerlach EH; Thornsberry C
    Diagn Microbiol Infect Dis; 1987 May; 7(1):29-35. PubMed ID: 3121241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1994 Feb; 38(2):369-70. PubMed ID: 8192468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers.
    Fuchs PC; Barry AL; Brown SD
    Antimicrob Agents Chemother; 1998 May; 42(5):1274-7. PubMed ID: 9593166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.